Similar results were seen in a phase II trial with advanced kidney cancer patients in which the anti-tumor effects of TM (decreased vascularity and tumor mass) were associated with lower serum copper and ceruloplasmin levels [24]. This evidence concerns the gene CP and kidney cancer.